Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis

Genes and Cancer

Volumn 2, Issue 4, 2011, Pages 466-474

  Rivlin, Noa ^a   Brosh, Ran ^a   Oren, Moshe ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

cancer; mutant; p53; tumorigenesis

Indexed keywords

CARCINOGEN; PROTEIN ANTIBODY; PROTEIN P53;

CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; EARLY DIAGNOSIS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 80053039210     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911408889     Document Type: Review

References (121)

1. Hanahan D,Weinberg RA.The hallmarks of cancer.Cell. 2000;100:57-70.
2. Berenblum I,Shubik P.A new, quantitative, approach to the study of the stages of chemical cartinogenesis in the mouse's skin.Br J Cancer. 1947;1:383-91.
3. Knudson AG.Mutation and cancer: statistical study of retinoblastoma.Proc Natl Acad Sci U S A. 1971;68:820-3.
4. Levine AJ,Oren M.The first 30 years of p53: growing ever more complex.Nat Rev Cancer. 2009;9:749-58.
5. Lane DP.Cancer.p53, guardian of the genome. Nature. 1992;358:15-6.
6. Aylon Y,Oren M.New plays in the p53 theater.Curr Opin Genet Dev. 2011;21:86-92.
7. Peller S,Rotter V.TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.Hum Mutat. 2003;21:277-84.
8. Ahmed AA,Etemadmoghadam D,Temple J, et al.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.J Pathol. 2010;221:49-56.
9. Petitjean A,Mathe E,Kato S, et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.Hum Mutat. 2007;28:622-9.
10. Malkin D,Li FP,Strong LC, et al.Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.Science. 1990;250:1233-8.
11. Hainaut P,Hollstein M.p53 and human cancer: the first ten thousand mutations.Adv Cancer Res. 2000;77:81-137.
12. Bullock AN,Fersht AR.Rescuing the function of mutant p53.Nat Rev Cancer. 2001;1:68-76.
13. Cho Y,Gorina S,Jeffrey PD,Pavletich NP.Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.Science. 1994;265:346-55.
14. Milner J,Medcalf EA,Cook AC.Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.Mol Cell Biol. 1991;11:12-9.
15. Milner J,Medcalf EA.Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.Cell. 1991;65:765-74.
16. Sigal A,Rotter V.Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.Cancer Res. 2000;60:6788-93.
17. Miller C,Mohandas T,Wolf D,Prokocimer M,Rotter V,Koeffler HP.Human p53 gene localized to short arm of chromosome 17.Nature. 1986;319:783-4.
18. Brosh R,Rotter V.When mutants gain new powers: news from the mutant p53 field.Nat Rev Cancer. 2009;9:701-13.
19. Oren M,Rotter V.Mutant p53 gain-of-function in cancer.Cold Spring Harb Perspect Biol. 2010;2:.
20. Fearon ER,Vogelstein B.A genetic model for colorectal tumorigenesis.Cell. 1990;61:759-67.
21. Cagatay T,Ozturk M.P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells.Oncogene. 2002;21:7971-80.
22. Hruban RH,Goggins M,Parsons J,Kern SE.Progression model for pancreatic cancer.Clin Cancer Res. 2000;6:2969-72.
23. Olivier M,Langerod A,Carrieri P, et al.The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Clin Cancer Res. 2006;12:1157-67.
24. Cohen C,DeRose PB.Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia.Mod Pathol. 1994;7:536-9.
25. Murakami Y,Hayashi K,Hirohashi S,Sekiya T.Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.Cancer Res. 1991;51:5520-5.
26. Oda T,Tsuda H,Scarpa A,Sakamoto M,Hirohashi S.p53 gene mutation spectrum in hepatocellular carcinoma.Cancer Res. 1992;52:6358-64.
27. Schlomm T,Iwers L,Kirstein P, et al.Clinical significance of p53 alterations in surgically treated prostate cancers.Mod Pathol. 2008;21:1371-8.
28. Kubota Y,Shuin T,Uemura H, et al.Tumor suppressor gene p53 mutations in human prostate cancer.Prostate. 1995;27:18-24.
29. Uchida T,Wada C,Ishida H, et al.p53 mutations and prognosis in bladder tumors.J Urol. 1995;153:1097-104.
30. Aubele M,Werner M,Hofler H.Genetic alterations in presumptive precursor lesions of breast carcinomas.Anal Cell Pathol. 2002;24:69-76.
31. Hieken TJ,Farolan M,D'Alessandro S,Velasco JM.Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.Surgery. 2001;130:593-600.
32. Iakova P,Timchenko L,Timchenko NA.Intracellular signaling and hepatocellular carcinoma.Semin Cancer Biol. 2011;21 (1): 28-34.
33. Louis DN.The p53 gene and protein in human brain tumors.J Neuropathol Exp Neurol. 1994;53:11-21.
34. Nozaki M,Tada M,Kobayashi H, et al.Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.Neuro Oncol. 1999;1:124-37.
35. Barrett MT,Sanchez CA,Prevo LJ, et al.Evolution of neoplastic cell lineages in Barrett oesophagus.Nat Genet. 1999;22:106-9.
36. Parkin DM,Pisani P,Ferlay J.Estimates of the worldwide incidence of 25 major cancers in 1990.Int J Cancer. 1999;80:827-41.
37. Wild CP,Jansen LA,Cova L,Montesano R.Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus.Environ Health Perspect. 1993;99:115-22.
38. Montesano R,Hainaut P,Wild CP.Hepatocellular carcinoma: from gene to public health.J Natl Cancer Inst. 1997;89:1844-51.
39. Aguilar F,Hussain SP,Cerutti P.Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes.Proc Natl Acad Sci U S A. 1993;90:8586-90.
40. Guengerich FP,Johnson WW,Ueng YF,Yamazaki H,Shimada T.Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.Environ Health Perspect. 1996;104 (Suppl 3): 557-62.
41. Buss P,Caviezel M,Lutz WK.Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1.Carcinogenesis. 1990;11:2133-5.
42. Staib F,Hussain SP,Hofseth LJ,Wang XW,Harris CC.TP53 and liver carcinogenesis.Hum Mutat. 2003;21:201-16.
43. Aguilar F,Harris CC,Sun T,Hollstein M,Cerutti P.Geographic variation of p53 mutational profile in nonmalignant human liver.Science. 1994;264:1317-9.
44. Toyooka S,Tsuda T,Gazdar AF.The TP53 gene, tobacco exposure, and lung cancer.Hum Mutat. 2003;21:229-39.
45. Greenblatt MS,Bennett WP,Hollstein M,Harris CC.Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.Cancer Res. 1994;54:4855-78.
46. Hainaut P,Pfeifer GP.Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.Carcinogenesis. 2001;22:367-74.
47. Petitjean A,Achatz MI,Borresen-Dale AL,Hainaut P,Olivier M.TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.Oncogene. 2007;26:2157-65.
48. Giglia-Mari G,Sarasin A.TP53 mutations in human skin cancers.Hum Mutat. 2003;21:217-28.
49. Benjamin CL,Melnikova VO,Ananthaswamy HN.P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer.Adv Exp Med Biol. 2008;624:265-82.
50. Benjamin CL,Ananthaswamy HN.p53 and the pathogenesis of skin cancer.Toxicol Appl Pharmacol. 2007;224:241-8.
51. Olivier M,Hainaut P.TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis.Semin Cancer Biol. 2001;11:353-60.
52. Rotter V,Witte ON,Coffman R,Baltimore D.Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50.J Virol. 1980;36:547-55.
53. DeLeo AB,Jay G,Appella E,Dubois GC,Law LW,Old LJ.Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.Proc Natl Acad Sci U S A. 1979;76:2420-4.
54. Melero JA,Stitt DT,Mangel WF,Carroll RB.Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells.Virology. 1979;93:466-80.
55. Kress M,May E,Cassingena R,May P.Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum.J Virol. 1979;31:472-83.
56. Crawford LV,Pim DC,Bulbrook RD.Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.Int J Cancer. 1982;30:403-8.
57. Lubin R,Schlichtholz B,Teillaud JL,Garay E,Bussel A,Wild CP.p53 antibodies in patients with various types of cancer: assay, identification, and characterization.Clin Cancer Res. 1995;1:1463-9.
58. Soussi T.p53 Antibodies in the sera of patients with various types of cancer: a review.Cancer Res. 2000;60:1777-88.
59. Lubin R,Zalcman G,Bouchet L, et al.Serum p53 antibodies as early markers of lung cancer.Nat Med. 1995;1:701-2.
60. Schlichtholz B,Tredaniel J,Lubin R,Zalcman G,Hirsch A,Soussi T.Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.Br J Cancer. 1994;69:809-16.
61. von Brevern MC,Hollstein MC,Cawley HM, et al.Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.Cancer Res. 1996;56:4917-21.
62. Ralhan R,Arora S,Chattopadhyay TK,Shukla NK,Mathur M.Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India.Int J Cancer. 2000;85:791-5.
63. Ralhan R,Nath N,Agarwal S,Mathur M,Wasylyk B,Shukla NK.Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.Clin Cancer Res. 1998;4:2147-52.
64. Hammel P,Leroy-Viard K,Chaumette MT, et al.Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.Int J Cancer. 1999;81:712-8.
65. Saffroy R,Lelong JC,Azoulay D, et al.Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.Br J Cancer. 1999;79:604-10.
66. Tavassoli M,Brunel N,Maher R,Johnson NW,Soussi T.p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity.Int J Cancer. 1998;78:390-1.
67. Soussi T. Analysis of p53 gene alterations in cancer: a critical view. In: Pierre Hainaut KGW, editor. 25 years of p53 research. New York: Springer; 2005. p. 255-92.
68. Zalcman G,Schlichtholz B,Tredaniel J, et al.Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.Clin Cancer Res. 1998;4:1359-66.
69. Cai HY,Wang XH,Tian Y,Gao LY,Zhang LJ,Zhang ZY.Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.World J Gastroenterol. 2008;14:4082-6.
70. Takeda A,Shimada H,Nakajima K, et al.Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability.Eur J Surg. 2001;167:50-3.
71. Kirk GD,Lesi OA,Mendy M, et al.249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.Oncogene. 2005;24:5858-67.
72. Lecomte T,Ceze N,Dorval E,Laurent-Puig P.Circulating free tumor DNA and colorectal cancer.Gastroenterol Clin Biol. 2010;34:662-81.
73. Haug U,Wente MN,Seiler CM,Jesnowski R,Brenner H.Stool testing for the early detection of pancreatic cancer: rationale and current evidence.Expert Rev Mol Diagn. 2008;8:753-9.
74. Atkin W,Martin JP.Stool DNA-based colorectal cancer detection: finding the needle in the haystack.J Natl Cancer Inst. 2001;93:798-9.
75. Mao L.Genetic alterations as clonal markers for bladder cancer detection in urine.J Cell Biochem Suppl. 1996;25:191-6.
76. Sidransky D,Von Eschenbach A,Tsai YC, et al.Identification of p53 gene mutations in bladder cancers and urine samples.Science. 1991;252:706-9.
77. Boyle JO,Mao L,Brennan JA, et al.Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas.Am J Surg. 1994;168:429-32.
78. Mao L,Hruban RH,Boyle JO,Tockman M,Sidransky D.Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.Cancer Res. 1994;54:1634-7.
79. Donehower LA,Harvey M,Slagle BL, et al.Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.Nature. 1992;356:215-21.
80. Attardi LD,Jacks T.The role of p53 in tumour suppression: lessons from mouse models.Cell Mol Life Sci. 1999;55:48-63.
81. Lang GA,Iwakuma T,Suh YA, et al.Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.Cell. 2004;119:861-72.
82. Heinlein C,Krepulat F,Lohler J,Speidel D,Deppert W,Tolstonog GV.Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.Int J Cancer. 2008;122:1701-9.
83. Muller PA,Caswell PT,Doyle B, et al.Mutant p53 drives invasion by promoting integrin recycling.Cell. 2009;139:1327-41.
84. Adorno M,Cordenonsi M,Montagner M, et al.A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.Cell. 2009;137:87-98.
85. Wang SP,Wang WL,Chang YL, et al.p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.Nat Cell Biol. 2009;11:694-704.
86. Chang CJ,Chao CH,Xia W, et al.p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.Nat Cell Biol. 2011;13 (3): 317-23.
87. Kogan-Sakin I,Tabach Y,Buganim Y, et al.Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.Cell Death Differ. 2011;18:271-81.
88. Muller PA,Vousden KH,Norman JC.p53 and its mutants in tumor cell migration and invasion.J Cell Biol. 2011;192:209-18.
89. Bossi G,Marampon F,Maor-Aloni R, et al.Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.Cell Cycle. 2008;7:1870-9.
90. Milyavsky M,Tabach Y,Shats I, et al.Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.Cancer Res. 2005;65:4530-43.
91. Tabach Y,Milyavsky M,Shats I, et al.The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation.Mol Syst Biol. 2005;1:.
92. Brosh R,Shalgi R,Liran A, et al.p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.Mol Syst Biol. 2008;4:229.
93. Buganim Y,Solomon H,Rais Y, et al.p53 regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.Cancer Res. 2010;70:2274-84.
94. Solomon H,Brosh R,Buganim Y,Rotter V.Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis.Discov Med. 2010;9:448-54.
95. Li FP,Fraumeni JF.Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.J Natl Cancer Inst. 1969;43:1365-73.
96. Li FP,Fraumeni JF.Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome?.Ann Intern Med. 1969;71:747-52.
97. Srivastava S,Zou ZQ,Pirollo K,Blattner W,Chang EH.Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.Nature. 1990;348:747-9.
98. Varley JM,McGown G,Thorncroft M, et al.Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors.Am J Hum Genet. 1999;65:995-1006.
99. Birch JM,Blair V,Kelsey AM, et al.Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.Oncogene. 1998;17:1061-8.
100. Song H,Hollstein M,Xu Y.p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.Nat Cell Biol. 2007;9:573-80.
101. Olive KP,Tuveson DA,Ruhe ZC, et al.Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.Cell. 2004;119:847-60.
102. Terzian T,Suh YA,Iwakuma T, et al.The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.Genes Dev. 2008;22:1337-44.
103. Barak Y,Juven T,Haffner R,Oren M.Mdm2 expression is induced by wild type p53 activity.EMBO J. 1993;12:461-8.
104. Haupt Y,Maya R,Kazaz A,Oren M.Mdm2 promotes the rapid degradation of p53.Nature. 1997;387:296-9.
105. Knoepfler PS.Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine.Stem Cells. 2009;27:1050-6.
106. Ben-Porath I,Thomson MW,Carey VJ, et al.An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat Genet. 2008;40:499-507.
107. Dean M,Fojo T,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer. 2005;5:275-84.
108. Reya T,Morrison SJ,Clarke MF,Weissman IL.Stem cells, cancer, and cancer stem cells.Nature. 2001;414:105-11.
109. Molchadsky A,Rivlin N,Brosh R,Rotter V,Sarig R.p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.Carcinogenesis. 2010;31 (9): 1501-8.
110. Molchadsky A,Shats I,Goldfinger N, et al.p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.PLoS ONE. 2008;3:e3707.
111. Shaulsky G,Goldfinger N,Rotter V.Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.Cancer Res. 1991;51:5232-7.
112. Matas D,Milyavsky M,Shats I,Nissim L,Goldfinger N,Rotter V.p53 is a regulator of macrophage differentiation.Cell Death Differ. 2004;11:458-67.
113. Aloni-Grinstein R,Zan-Bar I,Alboum I,Goldfinger N,Rotter V.Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.Oncogene. 1993;8:3297-305.
114. Wang Y,Yang J,Zheng H, et al.Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.Cancer Cell. 2009;15:514-26.
115. Hong H,Takahashi K,Ichisaka T, et al.Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.Nature. 2009;460:1132-5.
116. Kawamura T,Suzuki J,Wang YV, et al.Linking the p53 tumour suppressor pathway to somatic cell reprogramming.Nature. 2009;460:1140-4.
117. Li H,Collado M,Villasante A, et al.The Ink4/Arf locus is a barrier for iPS cell reprogramming.Nature. 2009;460:1136-9.
118. Marion RM,Strati K,Li H, et al.A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.Nature. 2009;460:1149-53.
119. Sarig R,Rivlin N,Brosh R, et al.Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.J Exp Med. 2010;207:2127-40.
120. Takenaka C,Nishishita N,Takada N,Jakt LM,Kawamata S.Effective generation of iPS cells from CD34(+) cord blood cells by inhibition of p53.Exp Hematol. 2010;38 (2): 154-62.
121. Zhao Y,Yin X,Qin H, et al.Two supporting factors greatly improve the efficiency of human iPSC generation.Cell Stem Cell. 2008;3:475-9.